2,4-dichloro-N-(propan-2-yl)benzamide | 39887-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,4-dichloro-N-(propan-2-yl)benzamide
• 英文别名: 2,4-dichloro-N-propan-2-ylbenzamide
• CAS: 39887-47-3
• 化学式: C₁₀H₁₁Cl₂NO
• mdl: MFCD00460878
• 分子量: 232.1
• InChiKey: OLOVOOIDPRZXNV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Cycloamine ccr5 receptor antagonists
  申请人：Shiota Tatsuki

  公开号：US20070010509A1

  公开（公告）日：2007-01-11

  Remedies or prophylactics for diseases in association with CCR5 such as AIDS, rheumatoid arthritis or nephritis comprising a cyclic amine compound represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable C 1 -C 6 alkyl addition salt thereof, as an active ingredient.

  本发明涉及与CCR5相关的疾病的治疗或预防措施，例如艾滋病、类风湿性关节炎或肾炎，包括下式（I）所表示的环状胺化合物，其药学上可接受的酸加盐或药学上可接受的C1-C6烷基加盐作为活性成分。
• SMALL MOLECULE MODIFIERS OF MICRORNA MIR-122
  申请人：Deiters Alexander

  公开号：US20130005759A1

  公开（公告）日：2013-01-03

  MicroRNAs are a class of endogenous regulators of gene function. Aberrant regulation of microRNAs has been linked to various human diseases, most importantly cancer. Small molecule intervention of microRNA misregulation has the potential to provide new therapeutic approaches to such diseases. microRNA miR-122 is the most abundant microRNA in the liver and is involved in hepatocellular carcinoma development and hepatitis C virus (HCV) infection. Small molecule inhibitors and activators of the microRNA miR-122 are described, and methods for their identification are reported. These small molecule inhibitors reduce viral replication in liver cells and thus represent a new approach to the treatment of HCV infections. Moreover, small molecule activation of miR-122 in liver cancer cells selectively induced apoptosis through caspase activation, and thus has implications in cancer chemotherapy.

  MicroRNAs是一类内源性基因调控因子。微小RNA的异常调控已与各种人类疾病，尤其是癌症相关联。小分子干预微小RNA的错调可能为这些疾病提供新的治疗方法。微小RNA miR-122是肝脏中最丰富的微小RNA，参与肝细胞癌的发展和丙型肝炎病毒（HCV）感染。描述了微小RNA miR-122的小分子抑制剂和激活剂，并报道了其鉴定方法。这些小分子抑制剂能够减少肝细胞中的病毒复制，因此代表了治疗HCV感染的新方法。此外，小分子激活miR-122在肝癌细胞中选择性地通过caspase激活诱导凋亡，因此在癌症化疗中具有重要意义。
• Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
  申请人：Rosalind Franklin University of Medicine and Science

  公开号：US10011578B2

  公开（公告）日：2018-07-03

  Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.

  本文公开了包含能够使神经元钙平衡失调正常化的化合物的方法和组合物。还公开了包含这些化合物的用于治疗神经元或神经系统疾病的方法，包括阿尔茨海默病、帕金森病、亨廷顿病、前颞叶痴呆症、皮克病、慢性创伤性脑萎缩、脑外伤、中风、小脑共济失调、多发性硬化症、唐氏综合征和衰老相关的中枢神经系统疾病。
• US20140275112A1
  申请人：——

  公开号：US20140275112A1

  公开（公告）日：2014-09-18
• Compounds For Stabilizing Ryanodine Receptors From Aberrant Levels Of Calcium Release
  申请人：Rosalind Franklin University of Medicine and Science

  公开号：US20160024038A1

  公开（公告）日：2016-01-28

  Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.